News & Sentiment
CINF Q2 Earnings Miss Estimates, Revenues Rise Y/Y on Premium Growth
Cincinnati Financial's Q2 results reflected premium growth and higher investment income, but elevated catastrophe losses hurt underwriting and earnings.
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
1,118 articles
📰
UnitedHealth Stock Has Rallied Big Since Berkshire Bailed. Did Warren Buffett and Greg Abel Blink Too Soon?
The conglomerate likely lost money on the investment, which has rallied in recent months.
📰
Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why
Pacific Biosciences of California (PACB) reached $1.39 at the closing of the latest trading day, reflecting a +2.21% change compared to its last...
Le club de football NASSR FC et HUMAIN annoncent un partenariat stratégique historique
Cet accord de grande envergure regroupe un partenariat de premier plan pour le maillot, les droits d'appellation du nouveau centre d'entraînement du...
📰
Jushi Holdings Inc. (JUSHF) Reports Q2 Loss, Tops Revenue Estimates
Jushi Holdings Inc. (JUSHF) delivered earnings and revenue surprises of +33.33% and +5.86%, respectively, for the quarter ended June 2026. Do the...
📰
Jushi Holdings Inc. (JUSHF) Reports Q2 Loss, Tops Revenue Estimates
Jushi Holdings Inc. (JUSHF) delivered earnings and revenue surprises of +33.33% and +5.86%, respectively, for the quarter ended June 2026. Do the...
📰
Chemed (CHE) Tops Q2 Earnings and Revenue Estimates
Chemed (CHE) delivered earnings and revenue surprises of +9.19% and +1.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues...
📰
Acadia Healthcare (ACHC) Surpasses Q2 Earnings and Revenue Estimates
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of +15.15% and +2.50%, respectively, for the quarter ended June 2026. Do the...
📰
Acadia Healthcare (ACHC) Surpasses Q2 Earnings and Revenue Estimates
Acadia Healthcare (ACHC) delivered earnings and revenue surprises of +15.15% and +2.50%, respectively, for the quarter ended June 2026. Do the...
📰
Why Cardinal Health (CAH) Outpaced the Stock Market Today
In the most recent trading session, Cardinal Health (CAH) closed at $232.51, indicating a +1.38% shift from the previous trading day.
📰
Vertex Pharmaceuticals (VRTX) Exceeds Market Returns: Some Facts to Consider
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $490.39, moving +2.38% from the previous trading session.
📰
Why Opko Health Stock Surged by 33% on Tuesday
It posted a beat-and-raise second quarter.
📰
Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing
Novo Nordisk (NVO) reached $50.96 at the closing of the latest trading day, reflecting a +2.6% change compared to its last close.
📰
CVS Health (CVS) Laps the Stock Market: Here's Why
CVS Health (CVS) closed the most recent trading day at $109.34, moving +2.12% from the previous trading session.
These 3 Companies Reported Record Results and Raised Guidance
Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking...
📰
BOARDWALK REIT AND DGAM CANADIAN PRIVATE REAL ESTATE FUND, L.P. ANNOUNCE STRATEGIC CO-OWNERSHIP TO EXPAND WESTERN CANADIAN MULTIFAMILY PLATFORM AND INITIAL $292 MILLION SEED PORTFOLIO
CALGARY, AB, July 28, 2026 /PRNewswire/ -- Boardwalk Real Estate Investment Trust ("Boardwalk", the "REIT" or the "Trust") (TSX: BEI.UN) and DGAM...
📰
Wall Street Says Buy the Dip in Viking Therapeutics. Here's the Bull Case
The stock looks like a high-risk, high-reward play.
📰
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market - MarketWatch
Thermo Fisher Scientific Inc. stock rises Tuesday, outperforms market MarketWatch
📰
Chemed Reports Second-Quarter 2026 Results
Chemed reports Q2 2026 results and increases full year guidance.
📰
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome
Expanded panel advances the understanding of immune system across translational and clinical research in cancer, cardiovascular and metabolic...
📰
Jushi Holdings Inc. Reports Second Quarter 2026 Financial Results
Revenue Increased 10% Year-over-Year to $71.3 million, Reflecting Growth Across Both Retail and Wholesale Channels
📰
Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference
REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive...
📰
Tilray Brands Delivers Record Fiscal 2026 Revenue and Adjusted EBITDA; Demonstrating the Strength of its Diversified Global Platform Across Cannabis, Beverage, Hospitality and Wellness
Record Fiscal Year Net Revenue of $915 Million, Record Gross Profit, Consistent Adjusted Gross Margin3 and Record Adjusted EBITDA5 Highlights the...
📰
Incyte Corporation (NASDAQ: INCY) lifts H1 2026 profit on drug sales and Vega deal - Stock Titan
Incyte Corporation (NASDAQ: INCY) lifts H1 2026 profit on drug sales and Vega deal Stock Titan
📰
3 Powerful AI Stocks Poised for the Next Massive Shift
AI's next winners may emerge from an overlooked part of the market. See how three software companies are turning proprietary expertise into a...
US Air Force awards Leidos ISR operations support task order worth up to $717 million
RESTON, Va., July 28, 2026 /PRNewswire/ -- As global threats become more complex, contested and fast-moving, U.S. airmen need timely intelligence...
📰
This Healthcare Leader Just Made a Bet on Artificial Intelligence (AI): Time to Buy the Stock?
Bristol Myers keeps making moves to establish a strong foundation for the future.
Should You Buy, Hold or Sell ABBV Stock Ahead of Q2 Earnings?
AbbVie heads into Q2 earnings with Skyrizi and Rinvoq driving growth as investors weigh Humira declines and the company's long-term outlook.
Ecolab Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
ECL stock rises pre-market after earnings and revenues beat estimates, as pricing, volume growth and core-business demand lift organic sales.
Ecolab Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
ECL stock rises pre-market after earnings and revenues beat estimates, as pricing, volume growth and core-business demand lift organic sales.
Ecolab Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
ECL stock rises pre-market after earnings and revenues beat estimates, as pricing, volume growth and core-business demand lift organic sales.
OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates
OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.
OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates
OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.
OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates
OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.
OPKO Health Stock Up as Q2 Earnings & Revenues Beat Estimates
OPK beats Q2 estimates as pharmaceutical growth, Nicoya income and lower costs narrow losses and lift shares pre-market.
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
INCY Q2 Earnings & Revenues Beat on Higher Sales, '26 View Raised
Incyte tops Q2 earnings and revenue estimates as Jakafi and Opzelura sales surged, prompting the company to raise its 2026 revenue outlook.
Can Pharmacy Wins and Home-Based Care Boost BTSG's Q2 Results?
BrightSpring heads into Q2 earnings with pharmacy and provider momentum, rising estimates and margin gains despite IRA and generic-conversion...
Can Pharmacy Wins and Home-Based Care Boost BTSG's Q2 Results?
BrightSpring heads into Q2 earnings with pharmacy and provider momentum, rising estimates and margin gains despite IRA and generic-conversion...
Can Pharmacy Wins and Home-Based Care Boost BTSG's Q2 Results?
BrightSpring heads into Q2 earnings with pharmacy and provider momentum, rising estimates and margin gains despite IRA and generic-conversion...
📰
Eli Lilly Just Made a $2.8 Billion Bet That Goes Beyond GLP-1 Drugs
The company isn't resting on its laurels.
Centene Q2 Earnings Beat Estimates on Increasing Premiums
CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.
Centene Q2 Earnings Beat Estimates on Increasing Premiums
CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.
Centene Q2 Earnings Beat Estimates on Increasing Premiums
CNC's Q2 earnings and revenues top estimates as stronger premium and service revenues drive results despite lower membership and higher medical costs.
Lupin Announces the Approval of Diazepam Injection, USP in the United States
MUMBAI, India, and NAPLES, Fla., July 28, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN)...
Here's How LLY's Non-GLP-1 Portfolio Is Poised Ahead of Q2 Earnings
Eli Lilly's expanding oncology and newer medicine portfolio is set to play a pivotal role in its Q2 earnings alongside its blockbuster GLP-1...